$Eli Lilly and Co (LLY.US)$
This is blasphemy against companies that have devoted significant research and development efforts over a period of 10 years. Anything goes, doesn't it!
[Reuters on the 19th] - The U.S. Food and Drug Administration (FDA) announced on the 19th that the supply shortage of the obesity and diabetes treatment drug from the pharmaceutical giant Eli Lilly (LLY.N) has been resolved after a reevaluation of the supply volume.
The FDA had allowed the creation of combination drugs based on the same ingredients to address the supply shortage of these pharmaceuticals. Despite the ban on selling these combination drugs in the future, the FDA explained that no action would be taken against pharmacies that have already produced the combination drugs within 60-90 days from this decision.
This is blasphemy against companies that have devoted significant research and development efforts over a period of 10 years. Anything goes, doesn't it!
[Reuters on the 19th] - The U.S. Food and Drug Administration (FDA) announced on the 19th that the supply shortage of the obesity and diabetes treatment drug from the pharmaceutical giant Eli Lilly (LLY.N) has been resolved after a reevaluation of the supply volume.
The FDA had allowed the creation of combination drugs based on the same ingredients to address the supply shortage of these pharmaceuticals. Despite the ban on selling these combination drugs in the future, the FDA explained that no action would be taken against pharmacies that have already produced the combination drugs within 60-90 days from this decision.
Translated
株の慶次
commented on
$NVIDIA (NVDA.US)$
OpenAI Continuous Announcement Event; Here is a summary of the contents of the 12th day announcement:
① Introduction of the new frontier models o3 and o3 mini: - o3 achieves performance surpassing human expert levels in mathematics, programming, and scientific fields with advanced reasoning capabilities. - o3 mini provides the 'Adaptive Thinking Time' feature, which excels in cost efficiency and allows adjustment of thinking time (low, medium, high) freely.
② Overwhelming performance in challenging benchmarks: - Significant performance improvements in various high-difficulty tests, surpassing the previous model (o1 series). - Especially in the ARC-AGI benchmark, it achieved a 87.5% accurate rate comparable to or exceeding human levels with increased computational complexity.
Enhancement of safety and "Deliberative Alignment": The model itself conducts detailed thinking internally to achieve more accurate safety determinations. Public safety tests are conducted, providing early access to researchers. Aim to establish a new safety protocol.
Future developments: o3 mini is planned to be publicly available at the end of January 2024, followed by o3. Further improvements and testing will ensure a high-reliability and powerful AI...
OpenAI Continuous Announcement Event; Here is a summary of the contents of the 12th day announcement:
① Introduction of the new frontier models o3 and o3 mini: - o3 achieves performance surpassing human expert levels in mathematics, programming, and scientific fields with advanced reasoning capabilities. - o3 mini provides the 'Adaptive Thinking Time' feature, which excels in cost efficiency and allows adjustment of thinking time (low, medium, high) freely.
② Overwhelming performance in challenging benchmarks: - Significant performance improvements in various high-difficulty tests, surpassing the previous model (o1 series). - Especially in the ARC-AGI benchmark, it achieved a 87.5% accurate rate comparable to or exceeding human levels with increased computational complexity.
Enhancement of safety and "Deliberative Alignment": The model itself conducts detailed thinking internally to achieve more accurate safety determinations. Public safety tests are conducted, providing early access to researchers. Aim to establish a new safety protocol.
Future developments: o3 mini is planned to be publicly available at the end of January 2024, followed by o3. Further improvements and testing will ensure a high-reliability and powerful AI...
Translated
+1
5
1
株の慶次
reacted to
$Eli Lilly and Co (LLY.US)$
800 keep! Do it!
800 keep! Do it!
Translated
2
$Upstart (UPST.US)$
I believe that the refinance rush will come somewhere.
I believe that the refinance rush will come somewhere.
Translated
3
$NVIDIA (NVDA.US)$
The fact that the resale residences are making a comeback means that there is downward pressure on the Core CPI.
The fact that the resale residences are making a comeback means that there is downward pressure on the Core CPI.
Translated
2
株の慶次
reacted to
$Eli Lilly and Co (LLY.US)$
Is it a company that says you will lose weight mentally when you buy shares of Eli Lilly and Co?
Is it a company that says you will lose weight mentally?
Is it a company that says you will lose weight mentally when you buy shares of Eli Lilly and Co?
Is it a company that says you will lose weight mentally when you buy shares of Eli Lilly and Co?
Is it a company that says you will lose weight mentally?
Is it a company that says you will lose weight mentally when you buy shares of Eli Lilly and Co?
Translated
23
株の慶次
reacted to
Translated
7
株の慶次
commented on
$Advanced Micro Devices (AMD.US)$ Pickles might be better? It seems that umeboshi can last for a hundred years. This is a big failure.
Translated
4
1